Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Elucidation of the role of
Ca2+
in the secretion of insulin and
glucagon
is complicated by the presence of different types of cells in the pancreatic islets. Visualization of
calcium
in sections of guinea pig pancreas with the histochemical reagent glyoxal bis-2-hydroxyanil revealed the most intense staining in the endocrine part but no differences between various islet cell types. A procedure for eliminating the majority of the beta-cells by streptozotocin injection in the guinea pig enabled a comparison of collagenase-isolated islets rich in alpha 2-cells with islets from untreated animals rich in beta-cells. The latter islets contained 24.6 +/- 2.4 mmol
calcium
/kg dry wt, as estimated by flameless atomic absorption spectrophotometry. This is twice as much as noted for the exocrine pancreas or the islets rich in alpha 2-cells. After storage for 3 days in culture medium, the two types of islets contained similar amounts of
calcium
. The cultured islets displayed differences related to cellular composition when measuring the incorporation of 45Ca into a lanthanum-nondisplaceable (intracellular) pool. In the presence of 3 mM glucose, more 45Ca was incorporated into the islets rich in alpha 2-cells. Increasing the glucose concentration to 20 mM with or without further addition of 30 U/liter bovine insulin was without effect on the 45Ca uptake into the islets rich in alpha 2-cells but stimulated that into islets rich in beta-cells. The different
calcium
dependence on glucose in the two types of islets may indicate that increased uptake of
Ca2+
is a component of the mechanism for the secretion of both insulin and
glucagon
.
...
PMID:Evidence for divergent glucose effects on calcium metabolism in pancreatic beta- and alpha 2-cells. 15 70
The possibility that hormones control hepatic gluconeogenesis via the regulation of the rate of mitochondrial pyruvate carboxylation was investigated with the use of suspensions of liver cells isolated from fasted rats. The mitochondria prepared from liver cells were judged in good condition as they exhibited satisfactory phosphorus-oxygen and respiratory control ratios and transported
Ca2+
and K+ ions in an energy-dependent manner. Addition of
glucagon
, epinephrine, or cyclic adenosine 3':5'-monophosphate to liver cells caused a 50 to 80% increase in the rate of glucose synthesis from lactate. When mitochondria were isolated from the cells after treatment with these agonists, they displayed 2- to 3-fold increases in the rate of pyruvate carboxylation, pyruvate decarboxylation, and pyruvate uptake. These mitochondrial changes are similar to those obtained in hepatic mitochondria prepared from intact, hormone-treated rats. The mitochondrial responses were specific for agents that stimulated gluconeogenesis; no response occurred with 5'-AMP or cyclic adenosine 2':3'-monophosphate. In the cell suspensions, the dose response curves for the activation of mitochondrial pyruvate metabolism and for increased glucose synthesis from L-lactate were coincident with four different agonists. The mitochondrial changes resulting from stimulation with
glucagon
developed in 1 to 2 min after the rise in cyclic adenosine 3':5'-monophosphate and occurred at least as early as the increase in the rate of gluconeogenesis. When the intracellular level of cyclic adenosine 3':5'-monophosphate returned to basal values, the rates of mitochondrial pyruvate carboxylation and glucose synthesis also declined to control levels. It is concluded that the rate of mitochondrial pyruvate metabolisms can be increased by hormones and cyclic nucleotides and that control of mitochondrial pyruvate carboxylation is an important regulatory site of hepatic gluconeogenesis.
...
PMID:The hormonal control of gluconeogenesis by regulation of mitochondrial pyruvate carboxylation in isolated rat liver cells. 16 52
An enzymatic method is described for isolating intact parenchymal cells from rat livers. 3--4 g cells (wet weight) could be isolated from livers of rats weighing 180--230 g. After an in vitro preperfusion of 15 minutes with a Ca-free buffer, collagenase (200 mg/1) and
calcium
chloride (5.2 mmol/1) were added. Perfusion was continued for another 15 minutes at 37 degrees C. Micromorphological integrity of cell membranes was demonstrated by scanning electron microscopy. With regard to rates of gluconeogenesis and protein synthesis, parenchymal cells isolated according to our method were found to be superior to liver slices and cells isolated by other methods. Ratios of ATP/ADP (5.69) and of lactate/pyruvate (8.64) as parameters of the energetic situation and the redox state resp. were found within the physiological range. Integrity of cell surface receptors was proved by their sensitivity to epinephrine,
glucagon
and insulin.
Glucagon
(0.3 mumol/1) and epinephrine (1 mumol/1) and reduced glycogen deposition in hepatocytes of fasted rats by 84.9 % and 95.9 % resp. Both hormones stimulated glycogenolysis in parenchymal cells of fed rats to a similar extent. Urea synthesis was stimulated 29.5 % by
glucagon
(1 mumol/1), and inhibited 28.0 % by insulin (10 nmol/1). The stimulatory effect of
glucagon
(1 mumol/1) was abolished by insulin (10 nmol/1).
...
PMID:[Isolation of intact liver parenchymal cells by a modified enzymatic method]. 16 41
Gluconeogenesis from lactate, pyruvate, fructose, alanine, and other substrates was accelerated by
glucagon
or epinephrine in hepatocytes isolated from rat liver.
Glucagon
and epinephrine also increased cyclic AMP accumulation by rat hepatocytes. Isoproterenol increased cyclic AMP but not gluconeogenesis, while phenylephrine accelerated gluconeogenesis. The activation of gluconeogenesis by epinephrine was unaffected by propranolol but blocked by dihydroergotamine. Dibutyryl cyclic AMP added to hepatocytes stimulated gluconeogenesis at concentrations as low as 1 muM. Exogenous cyclic GMP (0.1- muM) inhibited gluconeogenesis due to either
glucagon
or epinephrine without affecting basal gluconeogenesis. However, carbamylcholine did not affect gluconeogenesis by hepatocytes. Basal gluconeogenesis and the increases due to all agents were inhibited by removal of extracellular
calcium
or the presence of A-23187, D-600, or tetracaine. In contrast, added 0.1 muM cyclic GMP, 2 mM NH-4-Cl, and 10 muM phenethylbiguanide inhibited
glucagon
- or epinephrine-stimulated gluconeogenesis without affecting basal values. Studies with hepatocytes indicate that the hormonal activation of gluconeogenesis is not limited to substrates entering prior to triose phosphate formation.
Glucagon
may act by increasing cyclic AMP which acts via unknown mechanisms to increase gluconeogenesis. In contrast, epinephrine acts via a cyclic AMP-independent mechamism which does not appear to involve cyclic GMP, Ca-2+ flux, of K+ flux.
...
PMID:Cyclic nucleotides and gluconeogenesis by rat liver cells. 16 60
An insulin-producing islet cell tumor of the Syrian hamster has been studied in vitro for its capacity to respond to known stimuli of insulin release. Insulin secretion during short term incubation and perifusion of fragments of tumor was detected by radioimmunoassay. Insulin release was increased 2-4 fold by 40 mM potassium in the presence of
calcium
, glucose (22 mM),
glucagon
(0.3-3.0 muM), N6,02'-dibutyryl adenosine 3',5'-monophosphate (cAMP; 6mM), and theophylline (10 mM). Concentrations of
glucagon
that induced insulin release were also effective in activating adenylate cyclase in the membranes of tumor cells. Thus, this tumor appears to possess a cAMP-mediated mechanism for insulin release. Somatostatin (0.8-25 mum) inhibited
glucagon
-induced insulin release without altering basal or
glucagon
stimulated adenylate cyclase activity. It would appear that inhibition of
glucagon
induced insulin release by somatostatin is not mediated by adenylate cyclase. We propose that insulin release by this tumor is sufficiently similar to that found in normal islets so as to make it a suitable model for biochemical studies that require large quantities of homogeneous tissue.
...
PMID:Regulation of in vitro insulin release from a transplantable Syrian hamster insulinoma. 16 25
Glucagon
can stimulate gluconeogenesis from 2 mM lactate nearly 4-fold in isolated liver cells from fed rats; exogenous cyclic adenosine 3':5'-monophosphate (cyclic AMP) is equally effective, but epinephrine can stimulate only 1.5-fold. Half-maximal effects are obtained with
glucagon
at 0.3 nM, cyclic AMP at 30 muM and epinephrine at 0.2 muM. Insulin reduces by 50% the stimulation by suboptimal concentrations of
glucagon
(0.5 nM). A half-maximal effect is obtained with 0.3 nM insulin (45 microunits/ml).
Glucagon
in the presence of theophylline (1 mM) causes a rapid rise and subsequent fall in intracellular cyclic AMP with a peak between 3 and 6 min. Some of the fall can be accounted for by loss of nucleotide into the medium. This efflux is suppressed by probenecid, suggesting the presence of a membrane transport mechanism for the cyclic nucleotide.
Glucagon
can raise intracellular cyclic AMP about 30-fold; a half-maximal effect is obtained with 1.5 nM hormone. Epinephrine (plus theophylline, 1 mM) can raise intracellular cyclic AMP about 2-fold; the peak elevation is reached in less than 1 min and declines during the next 15 min to near the basal level. Insulin (10 nM) does not lower the basal level of cyclic AMP within the hepatocyte, but suppresses by about 50% the rise in intracellular and total cyclic AMP caused by exposure to an intermediate concentration of
glucagon
. No inhibition of adenylate cyclase by insulin can be shown. Basal gluconeogenesis is not significantly depressed by
calcium
deficiency but stimulation by
glucagon
is reduced by 50%. Calcium deficiency does not reduce accumulation of cyclic AMP in response to
glucagon
but diminishes stimulation of gluconeogenesis by exogenous cyclic AMP.
Glucagon
has a rapid stimulatory effect on the flux of 45Ca2+ from medium to tissue.
...
PMID:Hormonal control of cyclic 3':5'-AMP levels and gluconeogenesis in isolated hepatocytes from fed rats. 16 37
The influence of various agents on calcitonin release from human thyroid was studied in vitro. Under the condition of this investigation,
calcium
, magnesium and phosphate did not stimulate calcitonin release from short-term incubated slices of human thyroid. However, pentagastrin and USP
glucagon
were potent stimulators of calcitonin release. Theophylline and dibutyryl cyclic AMP were also potent stimuli. A highly purified preparation of pancreatic
glucagon
was without an effect. Those agents which stimulated calcitonin release were associated with augmented cyclic AMP accumulation. Although maximal discharge of calcitonin required the presence of
calcium
, out in vitro experiments raise the question as to whether a gastrointestinal hormone, rather than
calcium
, might not be the principal agent affecting calcitonin release.
...
PMID:In vitro studies of calcitonin release in man. 17 Dec 4
We studied nine consecutive hypocalcemic patients with acute pancreatitis to elucidate the mechanism of hypocalcemia. Mean serum ionized
calcium
, 0.97 mM, was below the normal mean of 1.16 mM (P less than 0.001). Seven of eight patients tested had normal parathyroid hormone levels. All responded to parenteral parathyroid extract by increasing serum ionized
calcium
and urinary cyclic AMP, indicating parathyroid-hormone-responsive target organs. Calcitonin and
glucagon
concentrations were increased above normal in some patients, but there was no relation with serum ionized
calcium
. Parenteral
glucagon
had no significant effect on serum ionized
calcium
or calcitonin concentrations. These findings suggest that neither
glucagon
nor calcitonin was primarily responsible for the hypocalcemia, which did not produce expected increases in serum parathyroid hormone concentrations. Relative parathyroid insufficiency may account for the persistent hypocalcemia frequently observed in patients with acute pancreatitis.
...
PMID:Inadequate parathyroid response in acute pancreatitis. 17 71
Insulin (10nM) completely suppressed the stimulation of gluconeogenesis from 2 mM lactate by low concentrations of
glucagon
(less than or equal to 0.1 nM) or cyclic AMP (less than or equal to 10 muM), but it had no effect on the basal rate of gluconeogenesis in hepatocyctes from fed rats. The effectiveness of insulin diminished as the concentration of these agonists increased, but insulin was able to suppress by 40% the stimulation by a maximally effective concentration of epinephrine (1 muM). The response to
glucagon
, epinephrine, or insulin was not dependent upon protein synthesis as cycloheximide did not alter their effects. Insulin also suppressed the stimulation by isoproterenol of cyclic GMP. These data are the first demonstration of insulin antagonism to the stimulation of gluconeogenesis by catecholamines. Insulin reduced cyclic AMP levels which had been elevated by low concentrations of
glucagon
or by 1 muM epinephrine. This supports the hypothesis that the action of insulin to inhibit gluconeogenesis is mediated by the lowering of cyclic AMP levels. However, evidence is presented which indicates that insulin is able to suppress the stimulation of gluconeogenesis by
glucagon
or epinephrine under conditions where either the agonists or insulin had no measurable effect on cyclic AMP levels. Insulin reduced the
glucagon
stimulation of gluconeogenesis whether or not extracellular
Ca2+
were present, even though insulin only lowered cyclic AMP levels in their presence. Insulin also reduced the stimulation by epinephrine plus propranolol where no significant changes in cyclic AMP were observed without or with insulin. In addition, insulin suppressed gluconeogenesis in cells that had been preincubated with epinephrine for 20 min, even though the cyclic AMP levels had returned to near basal values and were unaffected by insulin. Thus insulin may not need to lower cyclic AMP levels in order to suppress gluconeogenesis.
...
PMID:Regulation by insulin of gluconeogenesis in isolated rat hepatocytes. 17 43
Catecholamines increased guanosine 3':5'-monophosphate (cyclic GMP) accumulation by isolated rat liver cells. The increases in cyclic GMP due to 1.5 muM epinephrine, isoproterenol, or phenylephrine were blocked by phenoxybenzamine but not by propranolol. The possibility that cyclic GMP is involved in the glycogenolytic action of catecholamines seems unlikely since cyclic GMP accumulation is also elevated by carbachol, insulin, A23187, and to a lesser extent by
glucagon
. Furthermore, carbachol had little effect on glycogenolysis while insulin actually inhibited hepatic glycogenolysis. The rise in cyclic GMP due to carbachol was abolished by atropine and that due to all agents was markedly reduced by the omission of extracellular
calcium
. However, the glycogenolytic action of
glucagon
and catecholamines was only slightly inhibited by the omission of
calcium
. The only agent which was unable to stimulate glycogenolysis in
calcium
-free buffer was the divalent cation ionophore A23187. There was a drop in ATP content of liver cells during incubation in
calcium
-free buffer which was accompanied by an inhibition of
glucagon
-activated adenosine 3':5'-monophosphate (cyclic AMP) accumulation. The presence of
calcium
inhibited the rise in adenylate cyclase activity of lysed rat liver cells due to
glucagon
or isoproterenol but not that due to fluoride. These results suggest that the stimulation by catecholamines and
glucagon
of glycogenolysis is not mediated through cyclic GMP nor does it depend on the presence of extracellular
calcium
. Cyclic GMP accumulation was increased in liver cells by agents which either inhibit, have little affect, or accelerate glycogenolysis. The significance of elevations of cyclic GMP in rat liver cells remains to be established.
...
PMID:Studies on the role of cyclic guanosine 3':5'-monophosphate and extracellular Ca2+ in the regulation of glycogenolysis in rat liver cells. 17 60
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>